Hematology

A new genetic classification integrating co-mutations significantly refines risk stratification in NPM1-mutated AML and may guide allogeneic transplant decisions in first complete remission.

An all oral iberdomide based combination achieved a median progression free survival of 17.6 months in heavily pretreated patients with relapsed and refractory multiple myeloma.

Randomised trial shows intravenous iron significantly improves maternal haemoglobin before delivery in non-anaemic iron deficient pregnancy, supporting ferritin screening and targeted treatment in antenatal care.

Daratumumab-lenalidomide maintenance enhances MRD-negative conversion and reduces progression in multiple myeloma patients regardless of age, race, or cytogenetic risk.

An optimised OFA/iLRP aptamer forms a DNA nanostructure delivering doxorubicin selectively to AML cells, improving efficacy and reducing toxicity in preclinical models.

Researchers have identified serine threonine kinase 10 as a key regulator of platelet function, haemostasis and thromboinflammation.

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an investigational in vivo gene therapy…

Among patients treated in the first-line setting, the overall response rate was 57.1%, compared with 38.1% in those treated in the second line or later.